LAB Q4 2021 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q4 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$38M-14.2% YoY

Gross Profit

$20M52.9% margin

Operating Income

-$11M-29.4% margin

Net Income

-$9M-24.6% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+34.2%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$275M

Total Liabilities

$181M

Stockholders' Equity

$95M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$45M	-14.2%
Gross Profit	$20M	$26M	-22.8%
Operating Income	-$11M	-$17M	+33.4%
Net Income	-$9M	-$18M	+47.7%

Revenue Segments

Product

$31M45%

Consumables

$17M24%

Instruments

$15M21%

Service

$7M10%

Collaboration Revenue

$139,0000%

License

$54,0000%

Product and Service, Other

$54,0000%

Geographic Segments

Americas

$16M42%

EMEA

$14M37%

Asia Pacific

$8M20%